ArticleFrontiers in physiology2026
AB-Flu nanodrug combined with exercise intervention enhances ROS-mediated antitumor effects in melanoma.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to investigate the synergistic effects of AB-Flu nanodrugs and exercise intervention on enhancing the antitumor effects in melanoma by improving the hypoxic tumor microenvironment (TME). The focus is on evaluating how this combination influences reactive oxygen species (ROS) levels, inhibition of melanoma Methods: An intact B16F10 melanoma mouse model was established, and mice were divided into four groups: control, AB-Flu treatment, exercise intervention, and combination therapy (AB-Flu + exercise). AB-Flu nanodrug was administered intraperitoneally, while exercise was facilitated by a weighted swimming intervention. Tumor growth, tumor hypoxia, ROS levels, and apoptosis were analyzed through tumor volume measurements, histological staining, and ROS detection assays. The antitumor effects of different treatments were compared. Results: The combination therapy group showed the most significant tumor inhibition efficacy with tumor growth inhibition rates of 56%, compared to 30% for the AB-Flu monotherapy group and 41% for the exercise group. Additionally, tumor tissues from the combination group exhibited significantly lower levels of hypoxia and enhanced tumor cell apoptosis. ROS levels were substantially higher in the combination therapy group compared to other groups, indicating that the combination of AB-Flu and exercise synergistically elevated ROS production, which may contribute to increased tumor cell apoptosis. No significant toxicity was observed in major organs. Conclusion: The combination of AB-Flu nanodrugs and exercise intervention significantly enhances the antitumor effects in melanoma by improving the hypoxic TME, elevating ROS levels, and promoting apoptosis in tumor cells. This strategy may offer a potential approach for melanoma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.